Filtered By:
Drug: Fortamet
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 6534 results found since Jan 2013.
Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review
CONCLUSION: Three studies found that rs12208357, rs34059508, and G465R had a considerable impact (p < 0.05) on metformin pharmacokinetics, resulting in increased metformin plasma (Cmax), a higher active amount of drug in the blood (AUC), and lower volume of distribution (Vd) (p<0.05). SLC22A1 polymorphisms with effects on HbA1c include rs628031 (four of seven studies), rs622342 (four of six studies), rs594709 (one study), rs2297374, and rs1867351 (one of two studies), rs34130495 (one study), and rs11212617 (one study) (p < 0.05).PMID:37550919 | DOI:10.2174/1573399820666230807145202
Source: Current Diabetes Reviews - August 8, 2023 Category: Endocrinology Authors: Dimas Adhi Pradana Erna Kristin Dwi Aris Agung Nugrahaningsih Akhmad Kharis Nugroho Rizaldi Taslim Pinzon Source Type: research
Metformin alleviates glucolipotoxicity-induced pancreatic β cell ferroptosis through regulation of the GPX4/ACSL4 axis
In this study, we observed significant ferroptosis in NIT-1 cells and primary mouse islets after exposure to high glucose and palmitate (HG/PA). Compared to Exe and Sax, Met significantly alleviated glucolipotoxicity-induced pancreatic β cell ferroptosis. Blocking the activity of glutathione peroxidase 4 (GPX4) with Ras-selective lethal 3 or inhibiting its expression by small interfering RNA transfection significantly attenuated the anti-ferroptosis effects of Met. Mechanistically, Met alleviates HG/PA-induced β cell ferroptosis by regulating the GPX4/ACSL4 axis. Collectively, our findings highlight the significance of f...
Source: European Journal of Pharmacology - August 7, 2023 Category: Drugs & Pharmacology Authors: Yue Sun Li-Qun Guo De-Guo Wang Yu-Jie Xing Ya-Ping Bai Teng Zhang Wen Wang Si-Min Zhou Xin-Ming Yao Jin-Han Cheng Wei-Wei Chang Kun Lv Chun-Xiao Li Xiang Kong Source Type: research
Advanced effect of curcumin and resveratrol on mitigating hepatic steatosis in metabolic associated fatty liver disease via the PI3K/AKT/mTOR and HIF-1/VEGF cascade
This study aims to investigate the effect of curcumin (Cur) and resveratrol (Res) as a potential combination therapy on MAFLD. Cur, Res and Cur+Res were tested in palmitic acid (PA)-induced-HepG2 cells. MAFLD model was established using Goto-Kakizaki rats. The animals were treated with vehicle control (model group), Cur (150 mg/kg), Res (150 mg/kg), Cur+Res (150 mg/kg, 8:2, w/w), or metformin (Met, positive control, 400 mg/kg/day) via oral gavage for 4 weeks. Wistar rats were used as the control group. Network pharmacology was conducted to elucidate the molecular actions of Cur and Res, followed by q-PCR and immunoblotting...
Source: Biomed Res - August 6, 2023 Category: Research Authors: Yuhui He Huan Wang Shiling Lin Tao Chen Dennis Chang Yibin Sun Chenxiang Wang Yang Liu Yusheng Lu Jianyuan Song Shaohua Li Wen Xu Yanxiang Lin Yanfang Zheng Xian Zhou Qiumei Huang Mingqing Huang Source Type: research
Metformin-mediated epigenetic modifications in diabetes and associated conditions: biological and clinical relevance
Biochem Pharmacol. 2023 Aug 2:115732. doi: 10.1016/j.bcp.2023.115732. Online ahead of print.ABSTRACTAn intricate interplay between genetic and environmental factors contributes to the development of type 2 diabetes (T2D) and its complications. Therefore, it is not surprising that the epigenome also plays a crucial role in the pathogenesis of T2D. Hyperglycemia can indeed trigger epigenetic modifications, thereby regulating different gene expression patterns. Such epigenetic changes can persist after normalizing serum glucose concentrations, suggesting the presence of a 'metabolic memory' of previous hyperglycemia which may...
Source: Biochemical Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Authors: Roberta Giordo Anna Maria Posadino Arduino Aleksander Mangoni Gianfranco Pintus Source Type: research
Metformin beyond an anti-diabetic agent: A comprehensive and mechanistic review on its effects against natural and chemical toxins
Biomed Pharmacother. 2023 Aug 1;165:115263. doi: 10.1016/j.biopha.2023.115263. Online ahead of print.ABSTRACTIn addition to the anti-diabetic effect of metformin, a growing number of studies have shown that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer, genomic stability, anti-inflammation, and anti-fibrosis, which have potent, that can treat other disorders other than diabetes mellitus. We aimed to describe and review the protective and antidotal efficacy of metformin against biologicals, chemicals, natural, medications, pesticides, and radiation-induced toxicities. A comprehensiv...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 4, 2023 Category: Drugs & Pharmacology Authors: Amirhossein Malaekeh-Nikouei Sina Shokri-Naei Sobhan Karbasforoushan Hossein Bahari Vafa Baradaran Rahimi Reza Heidari Vahid Reza Askari Source Type: research
Metformin-mediated epigenetic modifications in diabetes and associated conditions: Biological and clinical relevance
Biochem Pharmacol. 2023 Aug 2;215:115732. doi: 10.1016/j.bcp.2023.115732. Online ahead of print.ABSTRACTAn intricate interplay between genetic and environmental factors contributes to the development of type 2 diabetes (T2D) and its complications. Therefore, it is not surprising that the epigenome also plays a crucial role in the pathogenesis of T2D. Hyperglycemia can indeed trigger epigenetic modifications, thereby regulating different gene expression patterns. Such epigenetic changes can persist after normalizing serum glucose concentrations, suggesting the presence of a 'metabolic memory' of previous hyperglycemia which...
Source: Biochemical Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Authors: Roberta Giordo Anna Maria Posadino Arduino Aleksander Mangoni Gianfranco Pintus Source Type: research
Metformin beyond an anti-diabetic agent: A comprehensive and mechanistic review on its effects against natural and chemical toxins
Biomed Pharmacother. 2023 Aug 1;165:115263. doi: 10.1016/j.biopha.2023.115263. Online ahead of print.ABSTRACTIn addition to the anti-diabetic effect of metformin, a growing number of studies have shown that metformin has some exciting properties, such as anti-oxidative capabilities, anticancer, genomic stability, anti-inflammation, and anti-fibrosis, which have potent, that can treat other disorders other than diabetes mellitus. We aimed to describe and review the protective and antidotal efficacy of metformin against biologicals, chemicals, natural, medications, pesticides, and radiation-induced toxicities. A comprehensiv...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - August 4, 2023 Category: Drugs & Pharmacology Authors: Amirhossein Malaekeh-Nikouei Sina Shokri-Naei Sobhan Karbasforoushan Hossein Bahari Vafa Baradaran Rahimi Reza Heidari Vahid Reza Askari Source Type: research
The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials
CONCLUSIONS: Metformin should be considered as an efficacious adjunct to lifestyle interventions in adults with PCOS, especially for those with a higher BMI, to improve weight loss, insulin resistance and lipids.PMID:37536294 | DOI:10.1093/ejendo/lvad098
Source: European Journal of Endocrinology - August 3, 2023 Category: Endocrinology Authors: Johanna Melin Maria Forslund Simon Alesi Terhi Piltonen Daniela Romualdi Poli Mara Spritzer Chau Thien Tay Alexia Pena Selma Feldman Witchel Aya Mousa Helena Teede Source Type: research
The great obstetrical syndromes and the placenta
BJOG. 2023 Aug 2. doi: 10.1111/1471-0528.17613. Online ahead of print.ABSTRACTAlthough historically pre-eclampsia, preterm birth, abruption, fetal growth restriction and stillbirth have been viewed as clinically distinct entities, a growing body of literature has demonstrated that the placenta and its development is the root cause of many cases of these conditions. This has led to the term 'the great obstetrical syndromes' being coined to reflect this common origin. Although these conditions mostly manifest in the second half of pregnancy, a failure to complete deep placentation (the transition from histiotrophic placentat...
Source: BJOG : An International Journal of Obstetrics and Gynaecology - August 2, 2023 Category: OBGYN Authors: Matthew K Hoffman Source Type: research
